First patient dosed in phase 2b trial of treatment for agitation in Alzheimer’s disease

IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.

In a press release, the company stated that the study, currently conducted at 12 locations across the United States and Canada, will assess IGC-AD1, a combination of a CB1 receptor partial agonist with anti-neuroinflammatory properties and an inflammasome inhibitor. Dosing was initiated at ClinCloud, a clinical research facility with two locations in Florida.

The study, which is expected to enroll 146 individuals, will randomize on a 1:1 basis treatment with IGC-AD1 or placebo, per the release.

“Treatment options targeting agitation in Alzheimer’s disease are currently limited,” Jessica Branning, ClinCloud’s founder, said in the release. “As the global population ages, it is more important than ever to identify treatments for neuropsychiatric conditions.”